Detrás de los titulares sobre el cáncer

Estudio: Más no es mejor: se puede reducir la dosis de PARP en pacientes con cáncer de ovario sin correr riesgos

Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)

Este artículo está disponible en español.

Actualización: Estrategias para tratar el dolor asociado con el cáncer de páncreas

Abdominal pain is often a severe, ongoing symptom of pancreatic cancer, yet little research has been done on how to best reduce this pain. The authors of this review discuss current strategies for managing cancer-related pain and their effectiveness. (Posted 10/31/22)

Este artículo está disponible en español.

Estudio: Ingerir alimentos que contienen almidón resistente puede ayudar a prevenir algunos tipos de cáncer en personas que padecen síndrome de Lynch

This study looked at whether a type of nutrient known as resistant starch could lower the risk of cancers in people with Lynch Syndrome. Researchers found that resistant starch can reduce the risk of non-colorectal cancers but not colorectal cancer. (Posted 10/17/22)

Este artículo está disponible en español.

Estudio: Los adolescentes y los adultos jóvenes responden bien al aprendizaje sobre el riesgo de cáncer familiar

Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022) Este artículo está disponible en español.

Actualización: Se retiran los inhibidores de PARP como tratamiento de tercera línea o posterior para el cáncer de ovario recurrente

Survival data from a clinical trial signaled that PARP inhibitors may not work as well as chemotherapy for patients with recurrent ovarian cancer who have received three or more lines of treatment. As a result, FDA approvals have been withdrawn for PARP inhibitors in this setting.  This does not affect PARP inhibitor approvals for use as maintenance therapy for ovarian cancer. (Posted 10/4/22)

Este artículo está disponible en español.

Estudio: La acupuntura puede aliviar los efectos secundarios del tratamiento contra el cáncer de mama

Acupuncture can ease some symptoms of breast cancer treatment. Multiple studies found that acupuncture is a safe and effective strategy to manage certain symptoms but also called for more rigorous research on the topic. (Posted 9/28/22) Este artículo está disponible en español.

Actualización: La FDA reporta nuevos tipos de cáncer asociados con implantes de seno

New cancers have been found in women with both textured and smooth implants that are filled with either saline or silicone. These cancers are extremely rare. The FDA has reported cases of a type of skin cancer and blood cancers in the scar tissue that forms around breast implants. The newly reported lymphomas are different from the previously reported breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). (Posted 9/27/22). Este artículo está disponible en español.

Estudio: La ampliación de la cobertura de Medicaid disminuyó las desigualdades raciales en las personas con cáncer de mama metastásico

The Affordable Care Act allowed more people to access insurance through Medicaid. This study found the expansion of care improved survival and decreased mortality among people of color with de novo stage 4 (stage 4 at the time of initial diagnosis) breast cancer.  (Posted 9/13/2022). Este artículo está disponible en español.

Estudio: El tratamiento con inhibidores de PARP para el cáncer de próstata metastásico muestra mayores beneficios en los hombres con mutaciones heredadas del BRCA

This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors.  (posted 9/6/2022)

Este artículo está disponible en español.

Estudio: Las pruebas de detección permiten diagnosticar el cáncer de páncreas en etapas iniciales y mejorar la supervivencia

A research study has shown that screening for pancreatic cancer in people with an inherited mutation or family history was able to detect early-stage pancreatic cancers and improve survival. These results will likely change pancreatic cancer screening guidelines for high-risk individuals (Posted 8/30/22)

Este artículo está disponible en español.